Acquired thrombophilic syndromes

Blood Reviews

Volumn 15, Issue 1, 2001, Pages 31-48

  Matei, Daniela ^a   Brenner, Benjamin ^b   Marder, Victor J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b RAMBAM MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIFIBRINOLYTIC AGENT; CARDIOLIPIN ANTIBODY; COUMARIN; ESTROGEN; HEPARIN; IMMUNOGLOBULIN; TAMOXIFEN; VON WILLEBRAND FACTOR;

ACUTE MYELOBLASTIC LEUKEMIA; ANTIPHOSPHOLIPID SYNDROME; BLOOD CLOTTING; BLOOD RHEOLOGY; DISEASE ASSOCIATION; ENDOTHELIUM CELL; FIBRINOLYSIS; GENE MUTATION; HORMONE SUBSTITUTION; HUMAN; HYPERCOAGULABILITY; MYELOPROLIFERATIVE DISORDER; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; SYNDROME DELINEATION; THROMBOEMBOLISM; THROMBOGENESIS; THROMBOPHILIA; VEIN THROMBOSIS;

EID: 0034987298     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1054/blre.2001.0148     Document Type: Article

References (334)

1. Phlogose und thrombose in gefilssystem
2. Lupus anticoagulants: Misnomer, paradox, riddle, epiphenomenon
3. Circulating anticoagulant as a cause of hemorrhagic diathesis in man
4. Thrombosis in systemic lupus erythematosus despite circulating anticoagulants
5. Coagulation screen is more specific than the anticardiolipin antibody ELISA in defining a thrombotic subset of lupus patients
6. Anticardiolipin antibodies: Detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus
7. Risk of arterial thrombosis in patients with anticardiolipin antibodies and lupus anticoagulant
8. Lupus anticoagulant, anticardiolipin antibodies, fetal loss and systemic lupus erythematosus
9. Criteria for the diagnosis of lupus anticoagulants: An update on behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardization Committee of the ISTH
10. Antibodies to β2-glycoprotein I, a specific marker for the antiphospholipid syndrome
11. Serum anti-β2-glycoprotein-1 and anticardiolipin antibodies during thrombosis in systemic lupus erythematosus patients
12. Clinical significance of a single test for anticardiolipin antibodies in patients with systemic lupus erythematosus
13. Fall in antiphospholipid antibody at time of thrombo-occlusive episodes in systemic lupus erythematosus
14. Multiple antiphospholipid tests do not increase the diagnostic yield in antiphospholipid syndrome
15. Inhibition of protein C activation by endothelial cells in the presence of lupus anticoagulant
16. Impaired catalytic function of activated protein C: A new in vitro manifestation of lupus anticoagulant
17. Effect of the lupus anticoagulant on endothelial fibrinolytic activity in vitro
18. Differences in protein S and C4b binding protein in different patients with antiphospholipid antibodies
19. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome
20. Activated protein C resistance: Molecular mechanisms
21. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo
22. Pregnancy loss in the antiphospholipid-antibody syndrome-a possible thrombogenic mechanism
23. No evidence for enhanced thrombin formation through displacement of annexin V by antiphospholipid antibodies
24. Antiphospholipid antibodies and venous thromboembolism
25. Deep venous thrombosis and lupus anticoagulant
26. Laboratory evaluation and clinical characteristics of 2,132 consecutive unselected patients with venous thromboembolism - Results of the Spanish multicentric study on thrombophilia (EMET-study)
27. Antiphospholipid-thrombosis syndromes
28. Coexistence of familial antiphospholipid syndrome and factor V Leiden: Impact on thrombotic diathesis
29. Multiple retinal arteriolar occlusions associated with coexistingrimary antiphospholipid syndrome and factor V Leiden mutation
30. The factor V Leiden mutation which predisposes to thrombosis is not common in patients with antiphospholipid syndrome
31. Lack of association between thrombosis in primary antiphospholipid syndrome and the recently described thrombophilic 3'-untranslated prothrombin gene polymorphism
32. Prothrombin mutation is not associated with thrombosis in patients with antiphospholipid syndrome
33. The 'primary' antiphospholipid syndrome: Major clinical and serological features
34. Antiphospholipid antibodies and thrombosis
35. Lupus anticoagulant in children with thrombosis
36. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus: A prospective analysis of 500 consecutive patients
37. Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders
38. Antiphospholipid antibody syndrome
39. Thrombotic and hemorrhagic complications in children with the lupus anticoagulant
40. Cerebral venous thrombosis with lupus anticoagulants. Report of two cases
41. Systemic lupus erythematosus presenting with portal venous thrombosis
42. Gastric bleeding due to splenic vein thrombosis
43. Occlusion of small hepatic veins associated with systemic lupus erythematosus with the lupus anticoagulant and anti-cardiolipin antibody
44. 'Lupus' anticoagulant and thrombosis of the hepatic veins (Budd-Chiari syndrome): Report of three patients and review of the literature
45. Renal vein thrombosis and inferior vena cava thrombosis in systemic lupus erythematosus: Frequency and risk factors
46. Lupus anticoagulant
47. Lupus anticoagulant: An analysis of the clinical and laboratory features of 219 cases
48. Antiphospholipid antibodies: A risk factor for occlusive ocular vascular disease in systemic lupus erythematosus and the 'primary' antiphospholipid syndrome
49. Bilateral massive adrenal hemorrhage: Early recognition and treatment
50. Asymptomatic intracardiac thrombi and primary antiphospholipid syndrome
51. Extensive cutaneous necrosis associated with anticardiolipin antibodies
52. Echocardiography in nonbacterial thrombotic endocarditis: From autopsy to clinical entity
53. Recurrent stroke and thrombo-occlussive events in the antiphospholipid syndrome
54. Cerebral microembolism, a disease marker for ischemic cerebrovascular events in the antiphospholipid syndrome of systemic lupus erythematosus?
55. Cerebrovascular ischemic events with high positive anticardiolipin antibodies
56. Catastrophic manifestations of the antiphospholipid syndrome
57. Catastrophic antiphospholipid syndrome with fatal acute course in rheumatoid arthritis
58. Catastrophic antiphospholipid antibody syndrome presenting with multiple thromboses and sites of avascular necrosis
59. Obstetrical implications of antiphospholipid antibodies
60. Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss, and a lupus anticoagulant
61. Lupus pregnancy. A prospective study of placental changes
62. Heparin therapy for pregnant women with lupus anticoagulant of anticardiolipin antibodies
63. Pregnancy complications in women with recurrent miscarriage associated with antiphospholipid antibodies treated with low dose aspirin and heparin
64. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated by enoxaparin
65. Pregnancy complicated by the antiphospholipid syndrome: Outcomes with intravenous immunoglobulin therapy
66. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy
67. Repeated fetal losses associated with antiphospholipid antibodies a collaborative randomized trial comparing prednisone with low-dose heparin treatment
68. Cerebral venous sinus thrombosis associated with the primary antiphospholipid syndrome. Resolution with local thrombolytic therapy
69. Therapeutic plasma exchange for the acute management of the catastrophic antiphospholipid syndrome: β(2)-glycoprotein 1 antibodies as a marker of response to therapy
70. Paroxysmal nocturnal haemoglobinuria
71. Somatic mutation and clonal selection in the pathogenesis and in the control paroxysmal nocturnal hemoglobinuria
72. The molecular basis of paroxysmal nocturnal hemoglobinuria
73. Deficiency of the complement regulatory protein, 'decay-accelerating factor,' on membranes of granulocytes, monocytes and platelets in paroxysmal nocturnal hemoglobinuria
74. Paroxysmal nocturnal haemoglobinuria. A clinicopathological study of 26 cases
75. Paroxysmal nocturnal hemoglobinuria first described in 1882 by Paul Strubing. An example of cooperation between clinical and basic research
76. Thromboplastic activity of the plasma in paroxysmal nocturnal haemoglobinuria
77. Elevated levels of circulating procoagulant microparticles in patients with paroxysmal nocturnal hemoglobinuria and aplastic anemia
78. Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria
79. The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria
80. Hematopoietic cells from spectrin-deficient mice are sufficient to induce thrombotic events in hematopoietically ablated recipients
81. Factor V Leiden mutation investigated by amplification created restriction enzyme site (ACRES) in PNH patients with and without thrombosis
82. Thrombosis in paroxysmal nocturnal hemoglobinuria with particular reference to progressive diffuse hepatic venous thrombosis
83. Cerebral venous thrombosis in paroxysmal nocturnal haemoglobinuria
84. Hepatic vein thrombosis in paroxysmal nocturnal hemoglobinuria: A spectrum from asymptomatic occlusion of hepatic venules to fatal Budd-Chiari syndrome
85. Budd-Chiari syndrome: Etiology, diagnosis and management
86. Fulminant hepatic venous thrombosis (Budd-Chiari syndrome) in paroxysmal nocturnal hemoglobinuria: Definition of a medical emergency
87. Hemorrhagic bullae in an anemic woman. Paroxysmal nocturnal hemoglobinuria
88. Skin lesions in paroxysmal nocturnal hemoglobinuria
89. Acute coronary artery thrombosis in paroxysmal nocturnal hemoglobinuria
90. Natural history of paroxysmal nocturnal hemoglobinuria
91. Paroxysmal nocturnal haemoglobinuria: Long-term follow-up and prognostic factors. French Society of Haematology
92. Thrombolytic therapy in inferior vena cava thrombosis in paroxysmal nocturnal hemoglobinuria
93. Tissue plasminogen activator for hepatic vein thrombosis in paroxysmal nocturnal hemoglobinuria
94. Pregnancy and paroxysmal nocturnal hemoglobinuria: Report of a case and review of the literature
95. Pregnancy and paroxysmal nocturnal hemoglobinuria
96. Prospective hemostatic studies in a patient having paroxysmal nocturnal hemoglobinuria, pregnancy, and cerebral venous thrombosis
97. Therapeutic dilemmas: Balancing the risks of bleeding, thrombosis and leukemic transformation in myeloproliferative disorders (MPD)
98. Splenectomy in myelofibrosis with myeloid metaplasia: A single-institution experience with 223 patients
99. Budd-Chiari syndrome and thrombosis of other abdominal vessels in the chronic myeloproliferative diseases
100. Complications of polycythemia vera
101. Natural history and management of polycythemia vera
102. Bleeding and thrombosis in the myeloproliferative disorders
103. Polycythemia vera
104. Thrombosis-free survival and life expectancy in 187 consecutive patients with essential thrombocythemia
105. Treatment of polycythemia vera
106. Treatment of polycythaemia vera and essential thrombocythaemia
107. Polycythemia vera
108. Vascular occlusive episodes and venous haematocrit in primary proliferative polycythaemia
109. Essential thrombocythemia
110. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis
111. Thrombotic complications in essential thrombocythemia with relatively low platelet counts
112. Erythromelalgic, thrombotic and haemorrhagic manifestations of thrombocythaemia
113. Erythromelalgic, thrombotic and hemorrhagic manifestations in 50 cases of thrombocythemia
114. The use of aspirin in polycythaemia vera and primary thrombocythaemia
115. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications
116. Thromboembolic complications of polycythemia: Polycythemmia vera versus smokers' polycythemia
117. Mechanisms of bleeding and thrombosis in myeloproliferative disorders
118. Increased thromboxane A2 biosynthesis in patients with polycythemia vera: Evidence for aspirin-suppressible platelet activation in vivo
119. Increased thromboxane biosynthesis in essential thrombocythemia
120. Influence of thrombopoietin on platelet activation in myeloproliferative disorders
121. Neurologic manifestations of essential thrombocythemia
122. Microvascular occlusive lesions in primary thrombocythaemia
123. Transient neurologic and ocular manifestations in primary thrombocythemia
124. Thromboxane-dependent platelet activation in vivo precedes arterial thrombosis in thrombocythaemia: A rationale for the use of low-dose aspirin as an antithrombotic agent
125. Thrombohaemmorrhagic complications in 101 cases of myeloproliferative disorders: Relationship to platelet number and function
126. The possible value of platelet aggregation studies in patients with increased platelet number
127. The clinical relevance of platelet aggregation study in myeloproliferative disorders
128. Bleeding and thrombosis in chronic myeloproliferative disorders: Relation of platelet disorders to clinical aspects of the disease
129. Thrombosis and bleeding in myeloproliferative disorders: Identification of at-risk patient with whole blood platelet aggregation studies
130. Reduced in vitro clot lysis and release of more active platelet PAI-I in polycythemia vera and essential thrombocythemia
131. Reduction of antithrobin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis
132. Homocysteine levels in polycythaemia vera and essential thrombocythaemia
133. Polycythemia vera: The natural history of 1213 patients followed for 20 years
134. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia
135. Hemorrhagic and thrombotic complications in polycythemia vera. A clinical study
136. Vascular complications of essential thrombocythaemia: A link to cardiovascular risk factors
137. Clinical course of essential thrombocythemia in 147 cases
138. Essential thrombocythemias. Clinical evolutionary and biological data
139. No treatment for low-risk thrombocythaemia: Results from a prospective study
140. In vitro colony culture and chromosomal studies in hepatic portal vein thrombosis - Possible evidence of an occult myeloproliferative state
141. Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders
142. Budd- Chiari syndrome associated with chronic myeloproliferative syndromes: Analysis of 6 cases
143. Portal, mesenteric, and splenic vein thromboses after splenectomy in a patient with chronic myeloid leukemia variant with thrombocythemic onset
144. Postpartum thrombosis in primary thrombocythaemia
145. Budd-Chiari syndrome caused by hepatic vein thrombosis in a patient with myeloproliferative disorder
146. Portal vein thrombosis in a 17-year-old female adolescent with essential thrombocytosis
147. Cerebral venous thrombosis as presenting sign of myeloproliferative disorders
148. Mesenteric venous thrombosis secondary to polycythemia vera
149. MR, CT, and ultrasonographic demonstration of splenic vein thrombosis
150. Portal hypertension in the myeloproliferative syndrome and the reticuloses
151. Low protein S in essential thrombocythemia with thrombosis
152. Hematologic causes of venous thrombosis in young people: High incidence of myeloproliferative disorder as underlying disease in patients with splenic venous thrombosis
153. The Budd-Chiari syndrome: Medical and surgical management of 30 patients
154. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with budd-chiari syndrome and portal vein thrombosis: Results of a case-control study
155. On a rare vaso-motor neurosis of the extremities and on the maladies with which it may be confounded
156. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols
157. The very long-term course of polycythaemia: A complement to the previously published data of the Polycythemia Vera Study Group
158. The role of α-interferon in essential thrombocythaemia, polycythaemia vera and myelofibrosis with myeloid metaplasia (MMM): A concise update
159. Interferon-α in the treatment of essential thrombocythemia
160. Interferon-α: Effects of long-term treatment for polycythemia vera
161. Anagrelide, a therapy for thrombocythemic states: Experience in 577 patients
162. Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera
163. Prevention and treatment of thrombotic complicatons in essential thrombocythaemia: Efficacy and safety of aspirin
164. Low-dose aspirin in polycythaemia vera: A pilot study
165. Aspirin seems as effective as myelosuppressive agents in the prevention of rethrombosis in essential thrombocythemia
166. Acute promyelocytic leukemia
167. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid)
168. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial
169. All-trans- retinoic acid as a differentiating agent in the treatment of acute promyelocytic leukemia
170. Early deaths and antihemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 286 consecutive patients
171. 'Microgranular' acute promyelocytic leukemia: A distinct clinical, ultrastructural and cytogenetic entity
172. A variant form of hypergranular promyelocytic leukemia (M3)
173. Pathologic cells as procoagulant substance of disseminated intravascular coagulation syndrome in acute promyelocytic leukemia
174. Hepatic vein thrombosis (Budd-Chiari Syndrome) in the microgranular variant of acute promyelocytic leukemia
175. The procoagulant factor of leukaemic cells: Demonstration of immunologic cross-reactivity with human brain tissue factor
176. A factor X activating cysteine protease from malignant tissue
177. Thrombin generation in acute promyelocytic leukemia
178. Studies of the procoagulant and fibrinolytic activity of promyelocytes in acute promyelocytic leukemia
179. The secretion of plasminogen activators by human myeloid leukemic cells in vitro
180. Acquired α-2-antiplasmin deficiency in acute promyelocytic leukemia
181. Hypofibrinogenemia due to increased fibrinolysis in two patients with acute promyelocytic leukemia
182. The bleeding disoder in acute promyelocytic leukaemia: Fibrinolysis due to u-PA rather than defibrination
183. Annexin II and bleeding in acute promyelocytic leukemia
184. Tranexamic acid for control of haemorrhage in acute promyelocytic leukemia
185. Epsilon-aminocaproic acid in the management of acute promyelocytic leukemia
186. Thrombosis in patients with acute promyelocytic leukemia treated with and without all-trans retinoic acid
187. Acute promyelocytic leukemia
188. Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selection on adherent platelets
189. The 'retinoic acid syndrome' in acute promyelocytic leukemia
190. Recurrent peripheral arterial occlusion by leukemic cells sedimentation in acute promyelocytic leukemia
191. All-trans retinoic acid: Not only a differentiating agent, but also an inducer of thromboembolic events in patients with M3 leukemia
192. Thrombotic complications in acute promyelocytic leukemia during all-trans- retinoic acid therapy
193. Influence of genetic predisposition to thrombosis on natural history of acute promyelocytic leukaemia
194. Beneficial effect of heparin in the management of patients with APL
195. Prophylactic heparin therapy in acute promyelocytiv leukemia
196. Early deaths and antihemorrhagic treatments an acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients
197. In vivo thrombin and plasmin activities in patients with acute promyelocytic leukemia (APL): Effect of all-trans retinoic acid (ATRA) therapy
198. Carcinoma and venous thrombosis: The frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis
199. Migratory nature of venous thrombi seen in 23 cases of carcinoma
200. Mucinous malignancies, venous thrombosis and terminal endocarditis with emboli. A syndrome
201. Hypercoaglability in cancer
202. Cancer and thrombosis
203. Cancer-related thromboembolic disease in patients with solid tumors: A retrospective analysis
204. Occult cancer in patients with venous thromboembolism: Which patients, which cancers
205. Pancreatic carcinoma and Trousseau's syndrome: Experience at a large cancer center
206. Venous thromboembolism and cancer
207. The role of platelet oxygenase and lipoxygenase pathways in tumor cell induced platelet aggregation
208. Characterization of platelet aggregative activity of tumor cells
209. Platelet tumor interactions in mice. The role of platelets in spread of malignant disease
210. Role of platelets in human tumor cell metastases
211. Correlation between spontaneous metastatic potential, platelet-aggregating activity of cell surface extracts and cell surface sialylation in 10 metastatic variant derivatives of a rat renal sarcoma cell line
212. Tissue factor activity of normal and leukemic cells
213. Tissue factor like activity of the human monocyte tumor cell line U-937
214. Immunohistochemical identification of tissue factor in solid tumors
215. A factor X activating cysteine protease from malignant tissue
216. Hemostatic abnormalities in untreated cancer. Incidence and correlation with thrombotic and hemorrhagic complications
217. Antithrombin III profiles in malignancy. Relationship to primary tumor and metastatic sites
218. Liver dysfunction rather than intravascular coagulation is the main cause of low protein C and antithrombin III in acute leukemia
219. Activated protein C resistance in cancer patients
220. Acquired activated protein C resistance is common in cancer patients with venous thromboembolism
221. Laboratory diagnosis of the thrombophilic state in cancer patients
222. Molecular species of plasminogen activators secreted by normal and neoplastic cells
223. The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer
224. Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer
225. The thrombophilic state induced by therapeutic agents in the cancer patient
226. Venous thromboembolism as first manifestation of cancer
227. Cardiac valvular vegetations in cancer patients: A prospective echocardiographic study of 200 patients
228. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms: Clinical, pathophysiologic and therapeutic features
229. Activation of blood coagulation in cancer: Trousseau's syndrome revisited
230. Trousseau's syndrome: Devastating coagulopathy in the absence of heparin
231. Low-molecular-weight heparin in the management of Trousseau's syndrome
232. Subcutaneous low-molecular-weight heparin for treatment of Trousseau's syndrome
233. Treatment of venous thromboembolism in cancer patients
234. Clinical results of Greenfield filter use in patients with cancer
235. Treatment of patients with venous thromboembolism and malignant disease: Should vena cava filter placement be routine?
236. Prevention of venous thromboembolism in cancer using low-molecular-weight heparins
237. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicenter trial with venographic assessment
238. Inhibition of metastasis by anticoagulants
239. Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study (#75)
240. Subcutaneous heparin treatment increases survival in small celt lung cancer
241. Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate. Final Report of VA Cooperative Study #75
242. Randomized trial of chemotherapy and radiation therapy with and without warfarin for limited stage small cell lung cancer. A Cancer and Leukemic Group B Study
243. Oral contraceptives and venous thromboembolism: Findings in a large prospective study
244. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease
245. Venous thromboembolic disease and combined oral contraceptives: Results of an international multicentre case control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid hormone Contraception
246. Effects on coagulation of levonorgestrel and desogestrel containing low dose oral contraceptives: A cross-over study
247. Renewed interest in haemostasis changes induced by oral contraceptives (Ocs)
248. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study
249. Risk of venous thromboembolism in users of hormone replacement therapy
250. Do lowered factor VII levels at extremely high endogenous oestradiol levels protect against thrombin formation?
251. Estrogen induction and contact phase activation of human factor X11
252. The effects of therapy with oestriol succinate and ethinyl oestradiol on the haemostatic mechanism in post-menopausal women
253. Paradoxical influence of estrogenic hormones on platelet-endothelial cell interactions
254. Platelet adhesion at low shear rate: Study of a normal population
255. Oral contraceptive steroid induced platelet coagulant hyperactivity: Dissociation of in vivo and in vitro effects
256. Effect of 17 β-estradiol on inhibition of platelet aggregation in vitro is mediated by an increase in NO synthesis
257. The effects of long-term therapy with oestriol succinate on the haemostatic mechanism in postmenopausal women
258. The comparative effects of a synthetic and a 'natural' oestrogen on the haemostatic mechanism in patients with primary amenorrhoea
259. Hormone replacement therapy, inflammation, and hemostasis in elderly women
260. Association between increased estrogen status and increased fibrinolytic potential in the Framingham Offspring Study
261. A randomized cross-over study on the effects of levonorgestrel and desogestrel-containing oral contraceptives on the anticoagulant pathways
262. Increased risk of venous thrombosis in oralcontraceptive users who are carriers of factor V Leiden mutation
263. Factor V Leiden: Should we screen oral contraceptive users and pregnant women?
264. Oral contraception and factor V Leiden mutation in relation to localization of deep vein thrombosis
265. Should oral contraceptive users be screened for factor V Leiden? Oral contraceptives are not the only effective contraceptives
266. Tamoxifen and risk of idiopathic venous thromboembolism
267. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
268. Medical adverse effects of chemoprevention: The example of tamoxifen
269. Effects of chemoendocrine therapy on the coagulation-fibrinolytic systems in patients with advanced breast cancer
270. The influence of tamoxifen in vivo on the main natural anticoagulants and fibrinolysis
271. Effects of tamoxifen on blood coagulation
272. Effect of tamoxifen on measurements of hemostasis in healthy women
273. Adjuvant antiestrogen treatment with tamoxifen in postmenopausal women with breast cancer: A longitudinal study of blood coagulation and fibrinolysis
274. Increased endogenous thrombin generation in children with acute lymphoblastic leukemia: Risk of thrombotic complications in I Asparaginase induced antithrombin III deficiency
275. Estramustine phosphate therapy in carcinoma of the prostate
276. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors
277. Prophylactic therapy with enoxaparin during L-asparginase treatment in children with acute lymphoblastic leukemia (ALL)
278. Importance of serotoninergic mechanisms in the thrombotic complications in hemodyalized patients treated with erythropoietin
279. The effect of preoperative recombinant human erythropoietin therapy on platelets and hemostasis in patients undergoing cardiac surgery
280. Effects of long term treatment with recombinant human erythropoietin on physiologic inhibitors of coagulation
281. Long-term effects of erythropoietin on platelet serotonin storage and platelet aggregation in hemodialysis patients with reference to ketanserin treatment
282. Erythropoietin and spontaneous platelet aggregation in hemodialysis patients
283. Cerebral venous thrombosis associated with epoietin alfa therapy
284. Integrated analysis of thrombotic/vascular event occurrence in epoetin alfa-treated patients undergoing major, elective orthopedic surgery
285. Effectiveness of perioperative recombinant erythropoietin in elective hip replacement
286. Erythropoietin therapy improves graft patency with no increased incidence of thrombosis or thrombophlebitis
287. Does the use of erythropoietin in hemodialysis patients increase dialysis graft thrombosis rates?
288. Adverse events of erythropoietin in long term and in acute/short term treatment
289. Thrombopoietin and thrombospondin in renal allograft recipients
290. Identification of a functional receptor for granulocyte colony stimulating factor on platelets
291. Effect of recombinant human granulocyte colony stimulating factor (rhG-CSF) on circulating platelets
292. Acute arterial thrombosis due to platelet aggregation in a patient receiving granulocyte colony-stimulating factor
293. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin
294. Petechiae, ecchymoses, and necrosis of skin induced by coumarin congeners
295. Coumarin-induced skin necrosis. Incidence, mechanisms, management and avoidance
296. Thrombotic complications of anticoagulant therapy
297. Acquired antithrombin III deficiency
298. Protein S deficiency occurs in the nephrotic syndrome
299. Total and free protein S in nephrotic syndrome
300. Acquired free protein S deficiency associated with multiple myeloma: A case report
301. Acquired protein S deficiency with multiple thrombotic complications after orthotopic liver transplant
302. Acquired protein S deficiency
303. Changes in protein C and protein S levels in normal pregnancy
304. Physiological coagulation inhibitors (protein S, protein C and antithrombin III) in severe pre-eclamptic states and in users of oral contraceptives
305. Acquired protein S deficiency occurs in pregnancy, the nephrotic syndrome and acute systemic lupus erythematosus
306. Protein S deficiency in patients with the lupus anticoagulant
307. Acquired free protein S deficiency is associated with antiphospholipid antibodies and increased thrombin generation in patients with systemic lupus erythematosus
308. Acquired protein S deficiency, likely due to anti-PS autoantibodies, following a thrombotic event in a patient with a systemic lupus erythematosus
309. Protein C and protein S levels in two patients with acquired purpura fulminans
310. Purpura fulminans and transient protein C and S deficiency
311. Severe autoimmune protein S deficiency in a boy with idiopathic purpura fulminans
312. Thrombophilic condition in HIV infected patients
313. Acquired protein S deficiency in children infected with human immunodeficiency virus
314. Protein S deficiency and HIV infection
315. Thrombosis and protein S deficiency in HIV infection
316. Protein deficiency in men with long-term human immunodeficiency virus infection
317. Budd-Chiari syndrome caused by Behcet's disease: Treatment by side-to-side portacaval shunt
318. Postoperative thrombosis of the superior caval vein in a patient with primary asymptomatic Behcet's disease. A case report
319. Pregnancy complicated by cerebral venous thrombosis in Behcet's disease
320. Intracardiac thrombus in Behcet's disease: A systematic review
321. Thrombophilic state in Behcet's disease
322. Thrombosis associated with the prothrombin G→A20210 mutation in Behcet's disease
323. Factor V Leiden mutation in patients with Behcet's disease
324. Activated protein C resistance caused by factor V Arg 506→Gln mutation has no role in thrombotic manifestations of Behcet's disease
325. Travel as a risk factor for venous thromboembolic disease; a case-control study
326. Travel and risk of venous thrombosis
327. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients
328. Risk factors for pregnancy associated venous thromboembolism
329. Thrombosis in pregnancy: Material and fetal issues
330. APC resistance and other haemostatic variables during pregnancy and puerperium
331. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy
332. Fibrinolysis in pregnancy: A study of plasminogen activator inhibitors
333. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium